Citius Pharmaceuticals, Inc.
NASDAQCTXR short interest climbs 20.7% over one week to 28.6% of float, while cost to borrow doubles to 95.7% — highest in months as availability plummets.
CTXR faces a rare three-way convergence. Short interest hit 29.6% of float. The options market just turned sharply bullish. And earnings drop today. Short interest rose 26.2% in one week to 29.6% of free float. That's…
Citius Pharmaceuticals heads into its May 19 earnings report carrying one of the most charged short setups in the small-cap pharma space. Short sellers have been piling in. Short interest as a percentage of free float…
Snapshot as of 28 Jun 2026
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CTXR — free to start on ORTEX.
Sign up for free →Open CTXR on ORTEX